HMGB1 and neoplasm: A recent nanoplatform designed by Sha et al. exemplifies this approach by simultaneously inducing tumor-selective ferroptosis through Fe2+/ROS generation and blocking HMGB1 release via glycyrrhizic acid loading, thereby attenuating ferroptosis-driven MDSCs recruitment and synergistically boosting immune checkpoint blockade efficacy [181] (Figure 3).